Open an account

Anthera Pharmaceuticals

ANTH · OTC

$0.0001+$0.0001 (+0.00%)TodayMarket closed ·
No price history for this range.

About ANTH

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Employees
21
Headquarters
Hayward, California
Listed
Mar 2, 2010
Sector
Health Care
Industry
Biotechnology
Website
anthera.com

Leadership

Anthera Pharmaceuticals executives
NameTitleSince
Paul Truex—2004
J. Craig Thompson—2016
May Liu——
Brent Furse——
Christopher Henney—2005
Brian Mueller——
Philip Sager——
David Thompson——

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Anthera Pharmaceuticals suppliers and customers
CompanyRelationshipCorrelation
Eli Lilly LLYSupplier and customer-0.39
Amgen AMGNSupplier and customer-0.75

Similar companies

Companies in the same industry as Anthera Pharmaceuticals

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.